Abstract
Oncolytic virotherapy is one of promising tumor therapy modalities. However, its therapeutic efficacy is still limited due to the immunogenicity and poor tumor-targeting capability. In this report, an engineered oncolytic vaccinia virus (OVV) was constructed by site-specifically introducing azide groups to the envelope of OVV during the in situ assembling process of virions. Subsequently, dibenzocyclooctynes (DBCO) derivate T7 peptide and DBCO derivate self-peptide were simultaneously conjugated to the azide-modified OVV (azide-OVV) via copper-free click chemistry. The infectivity of peptide-conjugated virus was well kept. Meanwhile, both of the targeting capacity to transferrin receptor (TfR)-overexpressed tumor cells and the in vivo blood circulation time increased. Therefore, the growth of TfR-positive tumor could be significantly inhibited after intravenously injecting the engineered OVV, while no noticeable side effects. This construction strategy can be popularized to other enveloped oncolytic virus (OV), thus a universal engineering platform can be provided for OV cancer therapy. [Figure not available: see fulltext.]
Original language | English |
---|---|
Pages (from-to) | 925-933 |
Number of pages | 9 |
Journal | Analytical and Bioanalytical Chemistry |
Volume | 411 |
Issue number | 4 |
DOIs | |
Publication status | Published - 1 Feb 2019 |
Keywords
- Azide-enabled oncolytic vaccinia virus
- Copper-free click chemistry
- Immunogenicity
- Oncolytic virotherapy
- Self peptide
- T7 peptide